In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients
| Autor: | Dah Hsi Ho, Susan Frisbee-Hume, Harriet Streeter, Kenneth V. I. Rolston, Barbara LeBlanc |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Microbiology (medical)
Moxifloxacin Microbial Sensitivity Tests Gram-Positive Bacteria medicine.disease_cause Enterococcus faecalis Microbiology Anti-Infective Agents Levofloxacin Neoplasms Drug Resistance Bacterial Gram-Negative Bacteria Streptococcus pneumoniae medicine Humans Aza Compounds biology Bacterial Infections General Medicine biochemical phenomena metabolism and nutrition bacterial infections and mycoses biology.organism_classification Antimicrobial Hospitalization Ciprofloxacin Stenotrophomonas maltophilia Infectious Diseases Viridans streptococci Quinolines bacteria Fluoroquinolones medicine.drug |
| Zdroj: | Diagnostic Microbiology and Infectious Disease. 47:441-449 |
| ISSN: | 0732-8893 |
| DOI: | 10.1016/s0732-8893(03)00115-9 |
| Popis: | The in vitro spectrum of moxifloxacin (a C-8-methoxyquinolone) was compared to that of ciprofloxacin and levofloxacin against 924 recent clinical isolates from cancer patients. Moxifloxacin was more active than the comparator agents against Gram-positive pathogens, with potent activity against Aerococcus spp., Listeria monocytogenes, Micrococcus spp., Rhodococcus equi, and Stomatococcus mucilaginous, methicillin-susceptible Staphylococcus spp., all beta hemolytic streptococci, viridans streptococci and Streptococcus pneumoniae. It also had good to moderate activity against Bacillus spp., Corynebacterium spp., Enterococcus faecalis, and methicillin-resistant staphylococci. Although ciprofloxacin was the most active agent tested against the Enterobacteriaceae, moxifloxacin inhibited the majority of these isolates at < or =2.0 microg/ml. Moxifloxacin was the least active of the three agents tested against Pseudomonas aeruginosa, but had significant activity against other non-fermentative Gram-negative bacilli including Acinetobacter spp., Flavobacterium spp., Pseudomonas spp. other than P. aeruginosa, and Stenotrophomonas maltophilia. The overall broad spectrum of moxifloxacin, and its availability for both oral and parenteral administration, warrants its evaluation for the prevention and treatment of infections in cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect